Slow binding-tight binding interaction between benzimidazol-2-one inhibitors and HIV-1 reverse transcriptase containing the lysine 103 to asparagine mutation

Antiviral Research

Volumn 86, Issue 3, 2010, Pages 268-275

  Samuele, Alberta ^a   Crespan, Emmanuele ^a   Vitellaro, Samanta ^a   Monforte, Anna Maria ^b   Logoteta, Patrizia ^b   Chimirri, Alba ^b   Maga, Giovanni ^a  

^a CNR   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Antiretroviral therapy; Benzimidazolones; Drug resistant HIV 1 mutant; Non nucleoside HIV 1 reverse transcriptase inhibitors

Indexed keywords

ASPARAGINE; CHI 452; CHI 465; EFAVIRENZ; LYSINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG;

ANTIVIRAL RESISTANCE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG BINDING SITE; DRUG POTENCY; DRUG STRUCTURE; ENZYME ANALYSIS; GENE EXPRESSION; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; MUTATION; PRIORITY JOURNAL;

AMINO ACID SUBSTITUTION; ASPARAGINE; BENZIMIDAZOLES; CELL LINE; CELL SURVIVAL; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; KINETICS; LYSINE; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTANT PROTEINS; MUTATION, MISSENSE; PROTEIN BINDING; REVERSE TRANSCRIPTASE INHIBITORS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77952675059     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.03.008     Document Type: Article

References (41)

1. Adamson C.S., Freed E.O. Novel approaches to inhibiting HIV-1 replication. Antiviral Res. 2010, 85:119-141.
2. Althaus I.W., Chou J.J., Gonzales A.J., Deibel M.R., Chou K.C., Kezdy F.J., Romero D.L., Aristoff P.A., Tarpley W.G., Reusser F. Steady-state kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-87201E. J. Biol. Chem. 1993, 268:6119-6124.
3. Althaus I.W., Chou J.J., Gonzales A.J., Deibel M.R., Chou K.C., Kezdy F.J., Romero D.L., Palmer J.R., Thomas R.C., Aristoff P.A., Tarpley W.G., Reusser F. Kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-88204E. Biochemistry 1993, 32:6548-6554.
4. Balzarini J., De Clercq E. Analysis of inhibition of retroviral reverse transcriptase. Methods Enzymol. 1996, 275:472-502.
5. Balzarini J., Pelemans H., Riess G., Roesner M., Winkler I., De Clercq E., Kleim J.P. Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2′,3′-dideoxy-3′-thiacytidine (lamivudine). Biochem. Pharmacol. 1998, 55:617-625.
6. Balzarini J., Van Laethem K., Hatse S., Vermeire K., De Clercq E., Peumans W., Van Damme E., Vandamme A.M., Bölmstedt A., Schols D. Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins. J. Virol. 2004, 78:10617-10627.
7. Barreca M.L., Rao A., De Luca L., Zappalà M., Monforte A.M., Maga G., Pannecouque C., Balzarini J., De Clercq E., Chimirri A., Monforte P. Computational strategies in discovering novel non-nucleoside inhibitors of HIV-1 RT. J. Med. Chem. 2005, 48:3433-3437.
8. Barreca M.L., De Luca L., Iraci N., Rao A., Ferro S., Maga G., Chimirri A. Structure-based pharmacophore identification of new chemical scaffolds as non-nucleoside reverse transcriptase inhibitors. J. Chem. Inf. Model. 2007, 47:557-562.
9. Beale K.K., Robinson W.E. Combinations of reverse transcriptase, protease, and integrase inhibitors can be synergistic in vitro against drug-sensitive and RT inhibitor-resistant molecular clones of HIV-1. Antiviral Res. 2000, 46:223-232.
10. Blanca G., Baldanti F., Paolucci S., Skoblov A.Y., Victorova L., Hübscher U., Gerna G., Spadari S., Maga G. Nevirapine resistance mutation at codon 181 of the HIV-1 reverse transcriptase confers stavudine resistance by increasing nucleotide substrate discrimination and phosphorolytic activity. J. Biol. Chem. 2003, 278:15469-15472.
11. Casado J.L., Hertogs K., Ruiz L., Dronda F., Van Cauwenberge A., Arnó A., Garcia-Arata I., Bloor S., Bonjoch A., Blazquez J., Clotet B., Larder B. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen. AIDS 2000, 14:F1-F7.
12. Cozzi Lepri A., Sabin C.A., Staszewski S., Hertogs K., Müller A., Rabenau H., Phillips A.N., Miller V. Resistance profiles in patients with viral rebound on potent antiretroviral therapy. J. Infect. Dis. 2000, 181:1143-1147.
13. Crespan E., Locatelli G.A., Cancio R., Hübscher U., Spadari S., Maga G. Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz. Antimicrob. Agents Chemother. 2005, 49:342-349.
14. de Béthune M.P. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). Antiviral Res. 2010, 85:75-90.
15. Esnouf R., Ren J., Ross C., Jones Y., Stammers D., Stuart D. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat. Struct. Biol. 1995, 2:303-308.
16. Fletcher R.S., Syed K., Mithani S., Dmitrienko G.I., Parniak M.A. Carboxanilide derivative non-nucleoside inhibitors of HIV-1 reverse transcriptase interact with different mechanistic forms of the enzyme. Biochemistry 1995, 34:4346-4353.
17. Hsiou Y., Ding J., Das K., Clark A.D., Hughes S.H., Arnold E. Structure of unliganded HIV-1 reverse transcriptase at 2.7Å resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure 1996, 4:853-860.
18. Hsiou Y., Das K., Ding J., Clark A.D., Kleim J.-P., Rösner M., Winkler I., Riess G., Hughes S.H., Arnold E. Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance. J. Mol. Biol. 1998, 284:313-323.
19. Huang H., Chopra R., Verdine G.L., Harrison S.C. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 1998, 282:1669-1675.
20. Jacobo-Molina A., Ding J., Nanni R.G., Clark A.D., Lu X., Tantillo C., Williams R.L., Kamer G., Ferris A.L., Clark P., Hizi A., Hughes S.H., Arnold E. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0Å resolution shows bent DNA. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:6320-6324.
21. Kohlstaedt L.A., Wang J., Friedman J.M., Rice P.A., Steitz T.A. Crystal structure at 3.5Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256:1783-1790.
22. Maga G., Ubiali D., Salvetti R., Pregnolato M., Spadari S. Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes. Antimicrob. Agents Chemother. 2000, 44:1186-1194.
23. Maggiolo F. Efavirenz: a decade of clinical experience in the treatment of HIV. J. Antimicrob. Chemother. 2009, 64:910-928.
24. Miller V., de Béthune M.P., Kober A., Sturmer M., Hertogs K., Pauwels R., Stoffels P., Staszewski S. Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. Antimicrob. Agents Chemother. 1998, 42:3123-3129.
25. Monforte A.M., Rao A., Logoteta P., Ferro S., De Luca L., Barreca M.L., Iraci N., Maga G., De Clercq E., Pannecouque C., Chimirri A. Novel N1-substituted 1,3-dihydro-2H-benzimidazol-2-ones as potent non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem. 2008, 16:7429-7435.
26. Monforte A.M., Logoteta P., Ferro S., De Luca L., Iraci N., Maga G., De Clercq E., Pannecouque C., Chimirri A. Design, synthesis, and structure-activity relationships of 1,3-dihydrobenzimidazol-2-one analogues as anti-HIV agents. Bioorg. Med. Chem. 2009, 17:5962-5967.
27. Monforte A.M., Logoteta P., De Luca L., Iraci N., Ferro S., Maga G., De Clercq E., Pannecouque C., Chimirri A. Novel 1,3-dihydro-benzimidazol-2-ones and their analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg. Med. Chem. 2010, 18:1702-1710.
28. Paolucci S., Baldanti F., Campanini G., Cancio R., Belfiore A., Maga G., Gerna G. NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine. Antiviral Res. 2007, 76:99-103.
29. Paredes R., Clotet B. Clinical management of HIV-1 resistance. Antiviral Res. 2010, 85:245-265.
30. Patel P.H., Jacobo-Molina A., Ding J., Tantillo C., Clark A.D., Raag R., Nanni R.G., Hughes S.H., Arnold E. Insights into DNA polymerization mechanisms from structure and function analysis of HIV-1 reverse transcriptase. Biochemistry 1995, 34:5351-5363.
31. Ragno R., Artico M., De Martino G., La Regina G., Coluccia A., Di Pasquali A., Silvestri R. Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives. J. Med. Chem. 2005, 48:213-223.
32. Ren J., Stammers D.K. Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase. Virus Res. 2008, 134:157-170.
33. Ren J., Esnouf R., Garman E., Somers D., Ross C., Kirby I., Keeling J., Darby G., Jones Y., Stuart D., Stammers D. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat. Struct. Biol. 1995, 2:293-302.
34. Ren J., Milton J., Weaver K.L., Short S.A., Stuart D.I., Stammers D.K. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure 2000, 8:1089-1094.
35. Ren J., Nichols C., Bird L.E., Fujiwara T., Sugimoto H., Stuart D.I., Stammers D.K. Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding. J. Biol. Chem. 2000, 275:14316-14320.
36. Rodriguez-Barrios F., Balzarini J., Gago F. The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations. J. Am. Chem. Soc. 2005, 127:7570-7578.
37. Samuele A., Kataropoulou A., Viola M., Zanoli S., La Regina G., Piscitelli F., Silvestri R., Maga G. Non-nucleoside HIV-1 reverse transcriptase inhibitors di-halo-indolyl aryl sulfones achieve tight binding to drug-resistant mutants by targeting the enzyme-substrate complex. Antiviral Res. 2009, 81:47-55.
38. Schäfer W., Friebe W.G., Leinert H., Mertens A., Poll T., von der Saal W., Zilch H., Nuber B., Ziegler M.L. Non-nucleoside inhibitors of HIV-1 reverse transcriptase: molecular modeling and X-ray structure investigations. J. Med. Chem. 1993, 36:726-732.
39. Shulman N., Winters M. A review of HIV-1 resistance to the nucleoside and nucleotide inhibitors. Curr. Drug Targets Infect. Disord. 2003, 3:273-281.
40. Sluis-Cremer N., Arion D., Parniak M.A. Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs). Cell Mol. Life Sci. 2000, 57:1408-1422.
41. Zhan P., Liu X., Li Z., Pannecouque C., De Clercq E. Design strategies of novel NNRTIs to overcome drug resistance. Curr. Med. Chem. 2009, 16:3903-3917.